Epitomee Medical Ltd. completes NIS 162 million IPO on the Tel Aviv Stock Exchange

Categories: Capital Markets

Epitomee Medical Ltd. has completed an IPO on the Tel Aviv Stock Exchange. As part of the IPO, Epitomee raised NIS 162 million for a valuation of NIS 632 million.

Epitomee’s groundbreaking technology allows a patient to receive biological treatment directly to the digestive system, by swallowing a capsule containing small medical devices, instead of intravenously or by injections.

Shibolet advised the issuer, with partner Itshak Cohen-Yehonatan and associate Omer Weiss advising on the IPO.